Jill Howe is the Chief Financial Officer for Lineage Cell Therapeutics (LCTX). She brings more than 20 years of experience in leading operational and financial strategy, treasury, global infrastructure, and compliance management across the biotechnology sector. In addition to the Codagenix Board, she serves on the Board of Directors and is the Chair of the Audit Committee for Biora, Inc. (BIOR). Prior to joining Lineage Cell Therapeutics, Jill was CFO for DTx Pharma. She was also previously Treasurer and Vice President of Finance for Gossamer Bio, a clinical-stage biopharmaceutical company, where she served as project lead for its public offering, including overseeing finance for 18 subsidiaries across the U.S. and Ireland. She also previously worked in Controller and Director of Finance roles at Amplyx Pharmaceuticals, Receptos, and Somaxon Pharmaceuticals. She received a Bachelor of Arts in Accountancy from San Diego State University.